Carlsmed (CARL) Competitors

Carlsmed logo
$17.38 +0.16 (+0.93%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$17.50 +0.12 (+0.69%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CARL vs. BFLY, LMAT, INSP, KMTS, and OMCL

Should you buy Carlsmed stock or one of its competitors? Carlsmed's main competitors and comparable companies include Butterfly Network (BFLY), LeMaitre Vascular (LMAT), Inspire Medical Systems (INSP), Kestra Medical Technologies (KMTS), and Omnicell (OMCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Carlsmed compare to Butterfly Network?

Carlsmed (NASDAQ:CARL) and Butterfly Network (NYSE:BFLY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

37.9% of Butterfly Network shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Butterfly Network has a net margin of -43.56% compared to Carlsmed's net margin of -55.82%. Butterfly Network's return on equity of -21.60% beat Carlsmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Carlsmed-55.82% -42.42% -30.87%
Butterfly Network -43.56%-21.60%-14.25%

Carlsmed presently has a consensus target price of $22.00, indicating a potential upside of 26.58%. Butterfly Network has a consensus target price of $8.75, indicating a potential upside of 62.34%. Given Butterfly Network's stronger consensus rating and higher possible upside, analysts plainly believe Butterfly Network is more favorable than Carlsmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Butterfly Network
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Carlsmed has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Carlsmed has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlsmed$50.51M9.43-$29.63M-$1.48N/A
Butterfly Network$97.61M14.77-$77.06M-$0.21N/A

In the previous week, Butterfly Network had 11 more articles in the media than Carlsmed. MarketBeat recorded 15 mentions for Butterfly Network and 4 mentions for Carlsmed. Butterfly Network's average media sentiment score of 0.46 beat Carlsmed's score of 0.14 indicating that Butterfly Network is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlsmed
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Butterfly Network
6 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Butterfly Network beats Carlsmed on 15 of the 16 factors compared between the two stocks.

How does Carlsmed compare to LeMaitre Vascular?

Carlsmed (NASDAQ:CARL) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, Carlsmed had 1 more articles in the media than LeMaitre Vascular. MarketBeat recorded 4 mentions for Carlsmed and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.24 beat Carlsmed's score of 0.14 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlsmed
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
LeMaitre Vascular
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Carlsmed has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

84.6% of LeMaitre Vascular shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LeMaitre Vascular has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlsmed$50.51M9.43-$29.63M-$1.48N/A
LeMaitre Vascular$249.60M6.75$57.73M$2.7526.77

Carlsmed currently has a consensus price target of $22.00, indicating a potential upside of 26.58%. LeMaitre Vascular has a consensus price target of $108.25, indicating a potential upside of 47.06%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Carlsmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
LeMaitre Vascular
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

LeMaitre Vascular has a net margin of 23.51% compared to Carlsmed's net margin of -55.82%. LeMaitre Vascular's return on equity of 15.33% beat Carlsmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Carlsmed-55.82% -42.42% -30.87%
LeMaitre Vascular 23.51%15.33%9.97%

Summary

LeMaitre Vascular beats Carlsmed on 9 of the 15 factors compared between the two stocks.

How does Carlsmed compare to Inspire Medical Systems?

Carlsmed (NASDAQ:CARL) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Inspire Medical Systems had 2 more articles in the media than Carlsmed. MarketBeat recorded 6 mentions for Inspire Medical Systems and 4 mentions for Carlsmed. Inspire Medical Systems' average media sentiment score of 0.81 beat Carlsmed's score of 0.14 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlsmed
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inspire Medical Systems
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Inspire Medical Systems has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlsmed$50.51M9.43-$29.63M-$1.48N/A
Inspire Medical Systems$911.98M1.75$145.42M$3.4415.98

Carlsmed presently has a consensus price target of $22.00, indicating a potential upside of 26.58%. Inspire Medical Systems has a consensus price target of $71.24, indicating a potential upside of 29.57%. Given Inspire Medical Systems' higher probable upside, analysts clearly believe Inspire Medical Systems is more favorable than Carlsmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Inspire Medical Systems
4 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.05

94.9% of Inspire Medical Systems shares are held by institutional investors. 12.9% of Carlsmed shares are held by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Carlsmed has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Inspire Medical Systems has a net margin of 11.43% compared to Carlsmed's net margin of -55.82%. Inspire Medical Systems' return on equity of 7.32% beat Carlsmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Carlsmed-55.82% -42.42% -30.87%
Inspire Medical Systems 11.43%7.32%6.39%

Summary

Inspire Medical Systems beats Carlsmed on 11 of the 16 factors compared between the two stocks.

How does Carlsmed compare to Kestra Medical Technologies?

Carlsmed (NASDAQ:CARL) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Carlsmed has a net margin of -55.82% compared to Kestra Medical Technologies' net margin of -140.43%. Carlsmed's return on equity of -42.42% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Carlsmed-55.82% -42.42% -30.87%
Kestra Medical Technologies -140.43%-63.83%-44.76%

Carlsmed has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Carlsmed has higher earnings, but lower revenue than Kestra Medical Technologies. Carlsmed is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlsmed$50.51M9.43-$29.63M-$1.48N/A
Kestra Medical Technologies$95.13M15.73-$131.61M-$2.67N/A

In the previous week, Kestra Medical Technologies had 4 more articles in the media than Carlsmed. MarketBeat recorded 8 mentions for Kestra Medical Technologies and 4 mentions for Carlsmed. Kestra Medical Technologies' average media sentiment score of 0.78 beat Carlsmed's score of 0.14 indicating that Kestra Medical Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlsmed
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kestra Medical Technologies
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Carlsmed presently has a consensus price target of $22.00, indicating a potential upside of 26.58%. Kestra Medical Technologies has a consensus price target of $29.00, indicating a potential upside of 15.40%. Given Carlsmed's higher possible upside, research analysts clearly believe Carlsmed is more favorable than Kestra Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Kestra Medical Technologies
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Carlsmed beats Kestra Medical Technologies on 7 of the 12 factors compared between the two stocks.

How does Carlsmed compare to Omnicell?

Carlsmed (NASDAQ:CARL) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Omnicell has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlsmed$50.51M9.43-$29.63M-$1.48N/A
Omnicell$1.18B1.26$2.05M$0.9633.86

Carlsmed presently has a consensus price target of $22.00, indicating a potential upside of 26.58%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 77.97%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than Carlsmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

97.7% of Omnicell shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Omnicell has a net margin of 3.59% compared to Carlsmed's net margin of -55.82%. Omnicell's return on equity of 5.69% beat Carlsmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Carlsmed-55.82% -42.42% -30.87%
Omnicell 3.59%5.69%3.61%

Carlsmed has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Omnicell had 10 more articles in the media than Carlsmed. MarketBeat recorded 14 mentions for Omnicell and 4 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.14 beat Omnicell's score of -0.07 indicating that Carlsmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlsmed
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Omnicell beats Carlsmed on 12 of the 16 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for CARL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CARL vs. The Competition

MetricCarlsmedHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$477.38M$5.79B$7.44B$10.86B
Dividend YieldN/A1.70%2.51%4.57%
P/E Ratio-11.7438.4132.5628.63
Price / Sales6.644.667.765.15
Price / CashN/A23.0420.2520.77
Price / Book6.304.114.343.51
Net Income-$29.63M$143.06M$3.51B$394.12M
7 Day Performance1.52%-7.11%-8.07%-8.97%
1 Month Performance18.96%-8.61%-10.29%-11.61%
1 Year Performance39.15%-4.03%-4.70%-11.21%

Carlsmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CARL
Carlsmed
2.0034 of 5 stars
$17.38
+0.9%
$22.00
+26.6%
+39.2%$477.38M$71.78MN/A127
BFLY
Butterfly Network
3.0327 of 5 stars
$6.08
-8.9%
$8.75
+44.0%
+104.2%$1.78B$97.61MN/A220
LMAT
LeMaitre Vascular
4.328 of 5 stars
$78.29
+0.8%
$108.25
+38.3%
-16.3%$1.78B$249.60M28.47655
INSP
Inspire Medical Systems
4.2957 of 5 stars
$61.16
+1.0%
$71.24
+16.5%
-38.8%$1.75B$911.98M17.781,333
KMTS
Kestra Medical Technologies
1.8736 of 5 stars
$28.64
+0.1%
$29.00
+1.3%
-3.7%$1.70B$95.13MN/A443

Related Companies and Tools


This page (NASDAQ:CARL) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners